Alexza shares should be bought ahead of marketing decision, says Roth Capital Roth Capital believes that Alexza's upcoming decision on a marketing route for its Adasuve treatment will most likely be positive for shareholders and the firm reiterates a Buy rating on the stock.
News For ALXA From The Last 14 Days
Check below for free stories on ALXA the last two weeks.
Alexza Pharmaceuticals announces U.S. commercial launch of Adusave by Teva Alexza Pharmaceuticals (ALXA) announced the U.S. commercial launch of ADASUVE inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries (TEVA). ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.